Pharmaceutical Technology

JUNE 13, 2023

As for safety, 85% had at least one Grade 3 or higher treatment-emergent adverse event (TEAE). According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

Patients 52

Patients Sales Competition Safety 52

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field.

Safety 59

Safety Sales Marketing Patients 59

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in sales in 2019, increasing to $136.2

Marketing 52

Marketing Physicians Leads Sales 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105